AstraZeneca, the maker of the antipsychotic drug Seroquel, is the defendant in a number of cases filed by over 9,000 people claiming that their use of Seroquel led to the development of diabetes. Recently, during a consolidated trial, a picture emerged of AstraZeneca selectively publishing data on Seroquel, thereby minimizing its risks. Several email messages and telephone messages seem to indicate that company officials sought to bury information that was unfavorable to Seroquel. Plaintiffs in the cases against AstraZeneca allege that Seroquel’s risks were not adequately presented. Currently approved uses of Seroquel include the treatment of schizophrenia, acute bipolar depression and mania, and bipolar 1 disorder. However, AstraZeneca hopes to obtain approval for an extended release form of Seroquel that could be used to treat generalized anxiety disorder and major depression.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.